Thalidomide NEW

Price	$35	$1.1
Package	1kg	1000kg

Min. Order:	1kg
Supply Ability:	g-kg-tons, free sample is available
Update Time:	2024-04-20

Product Details

Product Name: Thalidomide	CAS No.: 50-35-1
Min. Order: 1kg	Purity: 99%
Supply Ability: g-kg-tons, free sample is available	Release date: 2024/04/20
Lead time: In stock, ready for shipment	Packaging: bag/bottle/drum/IBC
Delivery: By express, by air, by sea	Origin: Manufacturer, advantage product
COA, MSDS: Available, contact us for details	Name: Mia

1. Materials information

Name	2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione
Synonym	More Synonyms

Description	Thalidomide is initially promoted as a sedative, inhibits ereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ∼250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> E1/E2/E3 Enzyme Research Areas >> Inflammation/Immunology Research Areas >> Cancer
Target	Kd: ∼250 nM (CRL4CRBN)[1]
In Vitro	Thalidomide is initially promoted as a sedative, has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties, and targets ereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ∼250 nM[1]. Thalidomide (50 μg/mL) potentiates the anti-tumor activity of icotinib against the proliferation of both PC9 and A549 cells, and this effect is correlated with apoptosis and cell migration. In addition, Thalidomide and icotinib inhibits the EGFR and VEGF-R2 pathways in PC9 cells[3].
In Vivo	Thalidomide (100 mg/kg, p.o.) inhibits the collagen deposition, down-regulates the mRNA expression level of α-SMA and collagen I, and significantly reduces the pro-inflammatory cytokines in RILF mice. Thalidomide alleviates RILF via suppression of ROS and down-regulation of TGF-β/Smad pathway dependent on Nrf2 status[2]. Thalidomide (200 mg/kg, p.o.) combined with icotinib shows synergistic anti-tumor effects in nude mice bearing PC9 cells, suppressing tumor growth and promoting tumor death[3].
Cell Assay	THP-1 cells, A549 cells and KYSE30 cells are cultured in RPMI-1640 Medium supplemented with 10% fetal bovine serum and maintained at 37 °C in an atmosphere of 5% CO2 and 95% room air. THP-1 cells is irradiated with a single dose of 4 Gy 6-MV X-ray and treated with or without Thalidomide (0.2 μmol/mL)-containing medium for 48 h after radiation. The concentration of Thalidomide is selected based on the preliminary results[2].
Animal Admin	Mice[2] A total of 24 WT C57BL/6 mice are randomly divided into 4 groups for the experiments (n = 6 in each group): a control group, an irradiated group, a group irradiated along with Thalidomide, and a Thalidomide only group. Based on the preliminary results, 100 mg/kg Thalidomide is used in the experiment. Thalidomide is dissolved in DMSO vehicle. The treatment group receives the indicated dose of Thalidomide in 200  μL by gavage every other day beginning on day 1 for six treatments. The control mice receives 200 μL 0.1% DMSO contained-saline only. The lungs are harvested at 12 weeks after irradiation for the analysis. A total of 20 Nrf2-/- mice are randomly divided into 4 groups for the experiments (n = 5 in each group). The experiment procedures of Nrf2-/- mice are the same as WT C57BL/6 mice. In addition, a total of 30 WT C57BL/6 mice are randomly divided into 5 groups for the subsequent experiments (n = 6 in each group): a control group, an irradiated group, a group irradiated along with CDDO-Me and Thalidomide, a group irradiated along with CDDO-Me, and a group irradiated along with Thalidomide. 600 ng and 100 mg/kg are selected as the dose of CDDO-Me and Thalidomide for the experiment, respectively. The treatment group receives the indicated dose of CDDO-Me or Thalidomide in 200 μL by gavage every other day beginning on day 1 for six times. For the combined group of CDDO-Me and Thalidomide, CDDO-Me is delivered in 200 μL by gavage every other day beginning on day 1 for six treatments. Thalidomide is delivered in 200  μL by gavage every other day beginning on day 2 for six treatments[2].
References	[1]. Fischer ES, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014 Aug 7;512(7512):49-53. [2]. Bian C, et al. Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. Free Radic Biol Med. 2018 Dec;129:446-453. [3]. Sun X, et al. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Med Sci Monit. 2018 May 15;24:3193-3203.

Density	1.5±0.1 g/cm3
Boiling Point	509.7±43.0 °C at 760 mmHg
Melting Point	269-271°C
Molecular Formula	C13H10N2O4
Molecular Weight	258.229
Flash Point	262.1±28.2 °C
Exact Mass	258.064056
PSA	83.55000
LogP	0.54
Vapour Pressure	0.0±1.3 mmHg at 25°C
Index of Refraction	1.646
Storage condition	Store at RT
Stability	Stable. Combustible. Incompatible with strong oxidizing agents.
Water Solubility	45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.6 mg/mL \| <0.1 g/100 mL at 22 ºC

Thalidomide MSDS(Chinese)

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TI4375000

CHEMICAL NAME :
Phthalimide, N-(2,6-dioxo-3-piperidyl)-

CAS REGISTRY NUMBER :
50-35-1

BEILSTEIN REFERENCE NO. :
0030233

LAST UPDATED :
199706

DATA ITEMS CITED :
85

MOLECULAR FORMULA :
C13-H10-N2-O4

MOLECULAR WEIGHT :
258.25

WISWESSER LINE NOTATION :
T56 BVNVJ C- DT6VMVTJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
113 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Administration onto the skin

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
1550 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
>6 gm/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
2 gm/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
800 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
>5 gm/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
>1538 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rabbit

DOSE/DURATION :
21500 mg/kg/43W-I

TOXIC EFFECTS :
Peripheral Nerve and Sensation - recording from afferent nerve

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
34 gm/kg/57W-I

TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - tumors at site of application Lungs, Thorax, or Respiration - tumors

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
2 mg/kg

SEX/DURATION :
female 30 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
17500 ug/kg

SEX/DURATION :
female 1-5 week(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
2 mg/kg

SEX/DURATION :
female 29 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
16 mg/kg

SEX/DURATION :
female 28-35 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
560 mg/kg

SEX/DURATION :
male 14 day(s) pre-mating

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
500 mg/kg

SEX/DURATION :
female 10-14 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
500 mg/kg

SEX/DURATION :
female 7-11 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
1050 mg/kg

SEX/DURATION :
female 1-21 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
28 gm/kg

SEX/DURATION :
male 3 day(s) pre-mating female 3 day(s) pre-mating - 22 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
200 mg/kg

SEX/DURATION :
female 15 day(s) pre-mating

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - skin and skin appendages Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
1200 mg/kg

SEX/DURATION :
female 9-11 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
22 mg/kg

SEX/DURATION :
female 6-9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

DOSE :
45 mg/kg

SEX/DURATION :
female 10 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - eye/ear

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

DOSE :
15 mg/kg

SEX/DURATION :
female 9-14 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

DOSE :
45 mg/kg

SEX/DURATION :
female 12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Unreported

DOSE :
1700 mg/kg

SEX/DURATION :
female 6-22 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
750 mg/kg

SEX/DURATION :
female 2-7 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
600 mg/kg

SEX/DURATION :
female 1-7 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
400 mg/kg

SEX/DURATION :
female 12-15 day(s) after conception

TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
155 mg/kg

SEX/DURATION :
female 7-11 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
124 mg/kg

SEX/DURATION :
female 7-10 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - abortion Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
25 mg/kg

SEX/DURATION :
female 9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
25 mg/kg

SEX/DURATION :
female 9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
100 mg/kg

SEX/DURATION :
female 13 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - other effects to embryo

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
2 gm/kg

SEX/DURATION :
female 11-12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
390 mg/kg

SEX/DURATION :
female 8-20 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Unreported

DOSE :
2 gm/kg

SEX/DURATION :
female 20-24 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Unreported

DOSE :
250 mg/kg

SEX/DURATION :
female 20-24 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
10 mg/kg

SEX/DURATION :
female 28 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
60 mg/kg

SEX/DURATION :
female 24-26 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
330 mg/kg

SEX/DURATION :
female 1-33 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
110 mg/kg

SEX/DURATION :
female 10-20 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
360 mg/kg

SEX/DURATION :
female 15-17 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - abortion Reproductive - Specific Developmental Abnormalities - homeostasis

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
150 mg/kg

SEX/DURATION :
female 7 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
450 mg/kg

SEX/DURATION :
female 7-9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
450 mg/kg

SEX/DURATION :
female 7-9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
400 mg/kg

SEX/DURATION :
female 7-16 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities Reproductive - Effects on Newborn - biochemical and metabolic

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
833 mg/kg

SEX/DURATION :
female 6-11 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - gastrointestinal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
125 mg/kg

SEX/DURATION :
female 8-12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Subcutaneous

DOSE :
1500 mg/kg

SEX/DURATION :
female 6-20 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - other developmental abnormalities Reproductive - Specific Developmental Abnormalities - body wall

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Subcutaneous

DOSE :
1700 mg/kg

SEX/DURATION :
female 1-17 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Subcutaneous

DOSE :
1800 mg/kg

SEX/DURATION :
female 3-20 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Subcutaneous

DOSE :
1200 mg/kg

SEX/DURATION :
female 1-20 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

DOSE :
750 mg/kg

SEX/DURATION :
female 6-10 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

DOSE :
12500 ug/kg

SEX/DURATION :
female 8-12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

DOSE :
10 mg/kg

SEX/DURATION :
female 7 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Unreported

DOSE :
900 mg/kg

SEX/DURATION :
female 7-12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - gastrointestinal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Unreported

DOSE :
1050 mg/kg

SEX/DURATION :
female 7-13 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Unreported

DOSE :
500 mg/kg

SEX/DURATION :
female 7 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
550 mg/kg

SEX/DURATION :
female 12-33 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
300 mg/kg

SEX/DURATION :
female 8 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
1500 mg/kg

SEX/DURATION :
female 8-12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
1800 mg/kg

SEX/DURATION :
female 13-18 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :
Unscheduled DNA synthesis

TYPE OF TEST :
Mutation test systems - not otherwise specified

MUTATION DATA

TEST SYSTEM :
Rodent - rat

DOSE/DURATION :
7600 mg/kg/30D (Continuous)

REFERENCE :
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 202,1080,1964 *** REVIEWS *** TOXICOLOGY REVIEW BCSTB5 Biochemical Society Transactions. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1973- Volume(issue)/page/year: 2,695,1974 TOXICOLOGY REVIEW PLMJAP Pahlavi Medical Journal. (Shiraz, Iran) V.1-9, 1970-78. Volume(issue)/page/year: 6,160,1975 TOXICOLOGY REVIEW AUHPAI Australian Journal of Hospital Pharmacy. (B.R. Miller, POB 125, Heidelberg, Vic., Australia) V.1- 1971- Volume(issue)/page/year: 4(1),5,1974 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 2,365,1973 TOXICOLOGY REVIEW INTEAG Internist. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1960- Volume(issue)/page/year: 15,7,1974 TOXICOLOGY REVIEW CLPTAT Clinical Pharmacology and Therapeutics (St. Louis). (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1960- Volume(issue)/page/year: 5,480,1964 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 TOXICOLOGY REVIEW ATXKA8 Archiv fuer Toxikologie. (Berlin, Fed. Rep. Ger.) V.15-31, 1954-74. For publisher information, see ARTODN. Volume(issue)/page/year: 28,135,1971 TOXICOLOGY REVIEW NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928- Volume(issue)/page/year: 267,1238,1962 TOXICOLOGY REVIEW NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928- Volume(issue)/page/year: 267,1184,1962 TOXICOLOGY REVIEW LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,45,1962 TOXICOLOGY REVIEW BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 2,646,1962 TOXICOLOGY REVIEW LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,303,1962

Symbol	GHS07, GHS08
Signal Word	Danger
Hazard Statements	H302-H360D
Precautionary Statements	P201-P280-P301 + P312 + P330-P308 + P313
Personal Protective Equipment	Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard Codes	T:Toxic
Risk Phrases	R46;R61;R21;R25;R62
Safety Phrases	S53-S22-S26-S36/37/39-S45
RIDADR	UN 2811 6.1/PG 3
WGK Germany	3
RTECS	TI4375000
Packaging Group	III
Hazard Class	6.1(b)
HS Code	2925190090

2. Packaging of materials

For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.
For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product.

Or smaller package 1kg/bottle, 10kgs/bottle as request.

Article illustration

3. Shipping & Delivery

By Express

Provide door to door service

Suitable for goods under 50kg

Delivery: 3-7 days

Cost: low cost

Article illustration

By Air

Provide airport to airport service

Suitable for goods over 50kg

Delivery: 3-14 days

Cost: high cost

Article illustration

By Sea

Provide seaport to seaport service

Suitable for goods over 100kg

Delivery: 2-45 days

Cost: low cost

Article illustration

4. Contact information

For more details, pls contact us freely.

Email address: mia@fdachem.com

Mob: 86 18336764634

WhatsApp/Skype/Wechat/LINE: 86 18336764634

Company Profile Introduction

Henan Fengda Chemical Co., Ltd. is located in the High-tech Development Zone of Henan Province. Specializing in the production and sales of various fine chemical products required for industrial production, including chemical raw materials, organic raw materials, petrochemicals, chemical reagents, solvents, catalysts, and additives, etc.

Recommended supplier

Product name	Price		Suppliers	Update time
Thalidomide	$10.00/1kg		Henan Bao Enluo International TradeCo.，LTD	2023-06-26
Thalidomide	$690.00/10kilograms	VIP3Y	Hebei Dangtong Import and export Co LTD	2023-02-17
Thalidomide	$0.00/25KG	VIP5Y	Hebei Mojin Biotechnology Co., Ltd	2022-07-11
Thalidomide	$35.00/1kg		Hebei baicao biology science and technology co., ltd	2022-04-06
Thalidomide	$1.00/10g		Guangzhou Biocar Biotechnology Co.,Ltd.	2022-01-19
Thalidomide	$19.00/1Kg/Bag		Hong Kong Tiansheng New Material Trading Co., Ltd	2022-01-07
Thalidomide	$1070.00/1g		Qiuxian Baitai New Material Co., LTD	2021-11-05
Thalidomide	$0.00/25KG		Hangzhou Huarong Pharm Co., Ltd.	2021-09-16
Thalidomide	$15.00/1KG		Zhuozhou Wenxi import and Export Co., Ltd	2021-08-11
Thalidomide	$0.00/1KG		WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD	2020-10-24